Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04665843 · ClinicalTrials.gov registry record · Phase 2

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

A Phase 2 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
123
Enrollment target
20
Study locations

NCT04665843 is a Phase 2 study of Squamous Cell Carcinoma of Head and Neck that has completed, run by Hoffmann-La Roche. The registered enrollment target is 123 participants, below the 167-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04665843, a Phase 2 study of Squamous Cell Carcinoma of Head and Neck, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) on the basis of confirmed objective response rate. In addition, safety, pharmacokinetics, immunogenicity of atezolizumab and tiragolumab will be evaluated.

Conditions Studied

Squamous Cell Carcinoma of Head and Neck

Interventions

  • DRUG Placebo
  • DRUG Atezolizumab
  • DRUG Tiragolumab

Study Locations (20)

Other

  • Masarykuv onkologicky ustav - Brno
  • Fakultni nemocnice Hradec Kralove - Hradec Králové
  • Fakultni nemocnice v Motole - Prague
  • CHU Bordeaux - Bordeaux
  • Centre Francois Baclesse - Caen
  • Centre Leon Berard - Lyon
  • Institut régional du Cancer Montpellier - Montpellier
  • Institut Curie - Paris
  • Institut de Cancérologie de Lorraine - Vandœuvre-lès-Nancy
  • Anticancer Hospital Ag Savas - Athens
  • Attiko Hospital University of Athens - Athens
  • Periph. University General Hospital of Heraklion Crete - Heraklion
  • Euromedical General Clinic of Thessaloniki - Thessaloniki

California

  • Moores Cancer Center at UC San Diego Health - La Jolla
  • UCLA - Los Angeles

Florida

  • SCRI Florida Cancer Specialists PAN - Tallahassee

Maryland

  • Johns Hopkins Hospital - Baltimore

Missouri

  • Washington University School of Medicine - St Louis

Tennessee

  • Tennessee Oncology - Nashville - Nashville

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2021-03-02
Est. Completion 2025-08-27
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04665843

The ClinicalTrials.gov registry entry for NCT04665843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 167-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (26% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04665843 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04665843 about?

NCT04665843 is a clinical study titled "A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck". The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) on the basis of confirmed objective response rate. I...

What is the current status of trial NCT04665843?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2021-03-02. Estimated completion is 2025-08-27.

What conditions does trial NCT04665843 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT04665843?

The interventions under investigation include: Placebo (DRUG), Atezolizumab (DRUG), Tiragolumab (DRUG).

Who is sponsoring clinical trial NCT04665843?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04665843 being conducted?

This trial has 20 study locations across California, Florida, Maryland, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.